Article source：
Aug 26,2026
View：
261 Kexing Biopharm’s licensed-in product infliximab biosimilar from Mabpharm Biotech (Reminton®) has recently been approved for marketing by the Thai Food and Drug Administration (Thai FDA). To date, the product has successfully gained market access in Peru, Indonesia, Pakistan, Bangladesh, Malaysia, and other countries and regions, marking steady progress in its international footprint.
Infliximab for Injection (Reminton) was approved by China’s National Medical Products Administration (NMPA) in 2021. It was the first infliximab biosimilar approved for marketing in China. The product is indicated for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, Crohn’s disease in adults and children aged 6 years and older, fistulizing Crohn’s disease, and ulcerative colitis in adults.
Autoimmune diseases are often chronic, progressive, and recurrent conditions that can be difficult to manage. Patients often require long-term and regular treatment and disease management. The entry of Reminton into the Thai pharmaceutical market will help provide local patients with an additional treatment option and alleviate the burden associated with long-term treatment.
Going forward, Kexing Biopharm will continue to work closely with outstanding partners in China and overseas to advance the global expansion of high-quality biologic medicines, making these treatments accessible to more patients around the world.
BACK TO LIST
Apr 09,2024
